Aliskiren

Administration

• Type: Antihypertensive
• Dosage Forms: 150mg, 300mg
• Routes of Administration: Oral
• Common Trade Names:

Adult Dosing

Hypertension

• 150-300 mg PO qd

Pediatric Dosing

Safety/efficacy not established in pediatric patients

Special Populations

• Pregnancy Rating: X
• Lactation risk: Consider alternative

Renal Dosing

• Adult:
  • CrCl > 30: No adjustment
  • CrCl < 30: Not Definied
  • HD/PD: No Supplement
• Pediatric: Safety/efficacy not established in pediatric patients

Hepatic Dosing

• Adult: No adjustment
• Pediatric: Safety/efficacy not established in pediatric patients

Contraindications

• Allergy to class/drug
• Pregnancy

Adverse Reactions

Serious

• Anaphylaxis, angioedema
• Stevens-Johnson syndrome, Toxic epidermal necrolysis
• Hypotension
• Hyperkalemia
• Renal failure, Nephrolithiasis

Common

• Diarrhea
• Hyperkalemia
• BUN, Cr elevation

Pharmacology

• Half-life: 24h
• Metabolism: Liver partially; 3A4 substrate
• Excretion: Urine (25% unchanged)

Mechanism of Action

• Decreases plasma renin activity via direct inhibition
• Interferes with conversion of angiotensinogen to angiotensin I